Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Positive Initial Results for Novel COVID-19 Drug Molnupiravir First Tested at Sheba

Studies indicate a quicker decline in the infectious virus among individuals with early COVID-19 treated with Molnupiravir

According to U.S. drugmaker Merck & Co Inc., initial results of studies on the experimental antiviral drug Molnupiravir it is developing with Ridgeback Bio suggest a reduction in the required duration for a negative COVID-19 indication from nasopharyngeal swab tests applied to study participants with early symptomatic COVID-19.

Sheba Medical Center was the first hospital in the world to collaborate with Merck & Co, Inc. and conduct a clinical trial of Molnupiravir on COVID-19, which was originally designed to combat the flu. Molnupiravir works by causing mutations in the enzyme responsible for replicating the virus.

Presently, Molnupiravir is in Phase II/III clinical trials, set to be completed by May.
“We are very pleased to share our initial Phase II infectivity data. At a time where there is an unmet need for antiviral treatments against COVID-19, we are encouraged by these preliminary data,” said Dr. Wendy Painter, Chief Medical Officer of Ridgeback Bio.


Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More
Hemophilia research
News Sep 05.

New Sheba Study Indicates: Novel Treatment Sharply Reduces Bleed Rates Among Hemophilia Patients

Results indicate that a monthly treatment with Fitusiran significantly reduces bleed rates among both hemophilia A and B patients.
Read More